HE development of SCS as a therapeutic modality for the management of chronic pain followed the initial description of the gate control theory of nociception in 1965. 22 Shealy and colleagues 28 reasoned that the electrical "gates" within the dorsal aspect of the spinal cord that were postulated by Melzack and Wall could be artificially stimulated by electrical current applied externally. The technology of SCS has evolved over the succeeding three decades, but the underlying concept remains unchanged. Modern SCS units consist of an electrical lead positioned in the epidural space overlying the dorsal spinal cord and a pulse generator that delivers a high-frequency, square-wave current. When the spinal cord is stimulated, patients describe a vibratory sensation in their extremities. This sensation is associated with a significant reduction of pain in the "stimulated" limbs. Since its introduction in 1967, SCS has been widely used for the treatment of chronic pain. 24, 30 This treatment is believed to alter neuronal inputs and synaptic activity within the dorsal horn of the spinal cord, thereby reducing central transmission of pain. Electrical conduction in the dorsal columns of the spinal cord has been thought to be modified by SCS, although this concept has been challenged. 4 The mechanism of action of SCS is the subject of heated debate, 30 although its efficacy in the alleviation of chronic pain is largely accepted.
although its efficacy in the alleviation of chronic pain is largely accepted.
Placement of the SCS leads varies widely according to clinical indications and patient anatomy. The leads are routinely placed in the cervical and in the thoracolumbar spine for the treatment of arm and leg pain, respectively. Optimal lead location for the treatment of pain in various regions has been the subject of some investigations. 2 Nevertheless, the location of the SCS lead is usually determined by clinical benefit, and may range from the top of the cervical spine to the conus medullaris at its lower end. Mathematical modeling of SCS has also been done in an effort to predict its effects on the spinal cord. Finite-element modeling work performed by Holsheimer and colleagues [8] [9] [10] has enabled accurate prediction of electrical contact geometries, providing optimal penetration of the dorsal aspect of the spinal cord.
Use of SCS in Peripheral and Myocardial Ischemia
A serendipitous discovery by Cook and others 5 while using SCS to treat ischemic limb pain in 1976 led them to postulate a direct effect on peripheral vascular tone. In this landmark paper, a patient is described in whom painful ischemic ulcers were observed in the lower extremities. Following the successful application of SCS, the patient's pain was alleviated. In addition, the perfusion to the lower extremities improved noticeably and the patient's ischemic ulcers began to heal. When SCS was stopped, the pain and (particularly noteworthy) the ulcers reappeared. Reestablishment of SCS once again resulted in improvement in the symptomatic peripheral ischemia. Since this initial observation was reported, the effects of SCS on vascular tone in the peripheral circulation have been studied extensively in the laboratory. [16] [17] [18] 23 Blood T flow in the rat hindpaw has been shown to rise dramatically in response to stimulation of the lumbar spinal cord. 16 It has also been reported that both chemical and surgical sympathectomy blunted the vascular response to SCS. 16, 17 Finally, SCS-induced blood flow changes were noted to occur despite transection of the rostral spinal cord or the dorsal nerve roots. Based on these lines of experimental evidence, researchers have suggested that SCS reduces peripheral sympathetic vascular tone, thereby augmenting blood flow in the limbs. 18 The therapeutic efficacy of SCS in the management of ischemic limb pain is now accepted. 14, 15, 33 It has also been suggested that SCS may reduce ischemic tissue injury in patients with peripheral vascular disease, although the data supporting this conclusion are mixed. 14, 15 Currently, application of SCS for symptomatic peripheral ischemia constitutes one of the most common indications for this treatment in Europe.
In addition to its use in peripheral vascular disease, SCS has been reported to be successful in reducing pain from myocardial ischemia. In a multicenter, randomized, prospective trial 19 it has been demonstrated that, far from masking incipient myocardial infarction, SCS is accompanied by improvement in coronary perfusion and inotropic performance. Furthermore, analysis of the data from this trial found that both coronary artery bypass grafting and SCS conferred similar protection from angina episodes and myocardial infarction over a 5-year period. 6 Equivalence has also been found between percutaneous revascularization and SCS. 20 When considered in aggregate, these observations indicate that SCS has a clinically significant vasodilatory effect in the peripheral vasculature and may even improve blood flow to ischemic tissue.
Use of SCS in Cerebral Ischemia
Because SCS has been shown to enhance peripheral vasodilation, it can also be considered for augmentation of cerebral perfusion. Changes in CBF related to SCS were the subject of an anecdotal report by Hosobuchi 11 involving a small number of patients who underwent stimulation for treatment of chronic pain. Hosobuchi and others 3, 12, 13 found that high cervical SCS increased CBF, although the extent of this augmentation and the underlying mechanisms have not been clearly defined. The possibility that CBF may be augmented with SCS has led to attempts to use stimulation in the treatment of cerebral ischemia. 3 Several investigators have applied SCS in experimental models of cerebral ischemia and in physiological preparations designed to measure CBF. 3, 7, 13, 21, 35 In goats and dogs, Garcia-March and colleagues 7 found that electrical stimulation at the C-2 spinal segment increased CBF by 55% when measured with laser Doppler flowmetry and by 35% when studied quantitatively by using iodoantipyrene autoradiography. Visocchi and coworkers 35 showed that CBF in rabbits will be increased by cervical SCS but can be attenuated by concurrent stimulation of the sympathetic trunk. Using a cat model, Isono and colleagues 13 found that CBF changes occurred only with SCS performed in the cervical spine. Moreover, these authors discovered that sectioning of the dorsal columns at the cervicomedullary junction abolished CBF changes. These findings have been corroborated independently in our laboratory by using a rat model of focal cerebral ischemia. 25, 26 The application of SCS also appears to result in a dramatic reduction of infarct volume in the setting of focal cerebral ischemia. 27 The experimental evidence accumulated to this point indicates that SCS has the capacity to improve cerebral perfusion and reverse ischemic injury in the brain, perhaps by alterations in sympathetic tone as well as indirect activation of brainstem or cerebellar vasomotor centers.
A number of clinical reports describing the use of SCS in the treatment of patients with cerebral ischemia have been published. Small numbers of patients and a variety of CBF measurement methods have been described in these reports, and investigators have suggested that SCS does indeed augment CBF during ischemia. In 2000, Takanashi and Shinonaga 31 published a report on a small series of patients who underwent SCS in the management of cerebral vasospasm following subarachnoid hemorrhage. These patients were studied before SCS was applied and 4 days after its use with xenon-inhalation computed tomography studies. The authors reported that regional CBF values were stable or slightly increased after the use of SCS, despite the fact that CBF normally decreases in patients over this time period. Moreover, there were no ad- Takanashi, 2001 in CBF w/ SCS verse events related to the use of SCS in patients with probable cerebral ischemia in any of these studies ( Table  1) . The available data on the use of SCS in cerebral ischemia in humans does not support the suggestion that there are significant ill effects associated with it. The efficacy of such an intervention is difficult to gauge, because the published studies are not designed to address this issue. Nevertheless, these studies, combined with the animal data and clinical experience with SCS for pain, provide a compelling reason for the investigation of the feasibility and utility of this intervention. In this study we have examined the therapeutic limits of SCS as an intervention for the treatment of acute cerebral ischemia. Specifically, we have examined the ability of SCS to reduce stroke volumes when applied after the ischemic insult. Because the clinical application of SCS would necessarily require that it be applied at some point after the onset of ischemia, this is a central issue in the applicability of this technology to patient care. Because current therapeutic interventions for acute stroke have been shown to be safe and effective for up to 3 hours after ischemia only, 1 in this study we chose to examine the effect of SCS when it was delayed for longer periods.
Materials and Methods

Animal Preparation
All experimental protocols were approved by the University of Michigan Committee on the Use and Care of Animals. Adult male Sprague-Dawley rats, each weighing between 250 and 350 g, were selected for the experimental series. The animals were housed in standard conditions in a laboratory environment with free access to food and water.
General anesthesia was induced with 5% isoflurane (Aerrane). After intubation and initiation of mechanical ventilation with a rodent ventilator (model 683; Harvard Apparatus, Inc.), isoflurane was titrated between 1.5 and 2.25% to maintain a mean arterial pressure between 80 and 120 mm Hg and a normal PaCO 2 level between 35 and 45 mm Hg. The rats were paralyzed with 10 mg/kg gallamine (Sigma Chemical Co.) given intravenously as a muscle relaxant. The animal's body temperature was maintained at 37˚C with an automatic heating device (model 73A-YSI; Yellow Springs Instruments). The femoral artery was cannulated for continuous monitoring of arterial blood pressure and arterial blood gas levels.
Occlusion of the MCA
We used the transcranial MCA occlusion model described by Tamura et al. 32 to induce permanent focal ischemia in the distribution of the MCA. An incision was made over the temporal aspect of the skull, and a craniectomy was fashioned with a bur drill. The zygomatic arch was also divided to provide adequate visualization. The dura mater was opened directly over the MCA, and the artery was coagulated with the aid of a bipolar electrocoagulator down to 1 mm below the level of the olfactory tract. The artery was then divided. The incision was closed, and the animal underwent placement of the spinal cord stimulator lead.
Spinal Cord Stimulation
The animal was placed in a stereotactic frame (model 900; Kopf Instruments). A midline incision was made from the occiput to the cervical spine. The first and second laminae were identified and cleared of paraspinous mus-
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Mechanisms of spinal cord stimulation in ischemia cles. The interspace between C-1 and C-2 was cleared, sparing the dura mater. A 1-mm platinum ball electrode was placed on the dura and secured in place. A ground electrode was placed in the soft tissues of the neck and the incision was closed. The wires were then brought out through the skin and connected to a standard stimulation setup, which consisted of a stimulator and a constant-current unit (models S48 and CCU1-A, respectively; Grass Instruments). Animals were awakened and allowed free access to food and water for the duration of the experiment. For the next 12 hours the rats were either stimulated immediately or in a progressively delayed fashion (starting at 3, 6, or 9 hours after MCA occlusion). Animals were stimulated with a square-wave pulse at an amplitude of 1.5 mA, frequency of 50 Hz, and pulse width of 250 msec. Two-minute stimulation trains were repeated every 10 minutes. These parameters were chosen based on optimal settings derived in previous studies conducted in our laboratory. 26, 27 A control group underwent insertion of the stimulator lead but received no stimulation throughout the experimental period. Animals were killed after the 12-hour postoperative period.
Analysis of Stroke Size
We assessed infarct size by staining the brain with the mitochondrial stain TTC (Sigma Chemical Co.) The brain was cut coronally at 2-mm intervals, and individual slices were soaked for 10 minutes in a solution of 2% TTC in 0.1 M phosphate-buffered saline (pH 7.4) in a 37˚C bath. Excess TTC was drained and the slices were refrigerated in a 10% formalin solution. Images were acquired by placing the brain sections on a color flatbed scanner that was connected to a computer running with image-analysis software (version 1.61; National Institutes of Health). Unstained regions were measured, and the percentage of the total slice area was calculated for each slice to attain a percentage of stroke volume.
Results
Our previous work has shown that SCS improves CBF in a model of focal ischemia in rats. 26 In the experimental series presented here we have extended this finding in an attempt to define the limits of such neuroprotection. We found that rats undergoing no stimulation had a 33% infarction of their hemisphere, as expected. Rats in which stimulation was started at periods as late as 6 hours after occlusion of the MCA experienced significantly smaller infarctions (11.3-13.5%). Even animals undergoing stimulation as late as 9 hours after ischemia seemed to have smaller infarction volumes, although this did not reach statistical significance (20.6% compared with 33% in the 9-hour compared with control group, p > 0.05). These findings are presented graphically in Fig. 1 . Representative sections from TTC-stained brains obtained in the different treatment groups are shown in Fig. 2 . Rats undergoing stimulation for the period of the experiment appeared to tolerate the treatment well. They exhibited no signs of discomfort when the stimulator was on.
Discussion
Electrical stimulation of the nervous system represents a unique opportunity to influence neural activity and physiology. The use of electrical stimulation in the treatment of pain is the prototype of this type of therapeutic intervention, but the number of applications of stimulation has grown significantly in the past several years. Electrical neurostimulation is now being used to treat movement disorders, myocardial ischemia, and psychiatric disorders. As the technology for delivering electrical impulses in the nervous system improves, our ability to expand the capabilities of this modality continues to advance. As a case in point, the use of SCS to improve CBF appears to extend the window of therapeutic efficacy in an experimental model. A full 6 hours after occlusion of the MCA, SCS appears to confer significant protection from infarction. We are currently investigating the length of time it is necessary to deliver electrical stimulation after the onset of ischemia. It is our hope that a stimulator lead placed percutaneously while the patient is in the emergency department will allow clinicians to ameliorate acute stroke in individuals who are not candidates for thrombolytic therapy.
